Last reviewed · How we verify

NCT05438017

Performance Evaluation of the Dreem 3 System for Sleep Assessment in Patients With Insomnia

Completed NA Last updated 29 July 2022
What this trial tests

NA trial testing Dreem 3 System vs PSG in Insomnia in 41 participants. Completed in 8 July 2022.

Timeline
21 April 2022
Primary endpoint
8 July 2022
8 July 2022

Quick facts

Lead sponsorDreem
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment41
Start date21 April 2022
Primary completion8 July 2022
Estimated completion8 July 2022
Sites2 locations across France, United States

Drugs / interventions tested

Conditions studied

Sponsor

Dreem

Who can join

Adults 22 to 70, any sex, with Insomnia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the clinical investigation is to assess the performance of the Dreem 3 System for sleep assessment compared to a FDA-cleared PSG assessment and human sleep expert scoring in a population experiencing insomnia symptoms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Insomnia

Currently open trials in the same condition.

Other Dreem trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05438017.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing